Drug intelligence / Profile preview

EBVpoly

Development stage: Preclinical
Lead developer: Atara Biotherapeutics
Modality: Cell Therapies
Administration: Intramuscular, Subcutaneous, Intraperitoneal

Overview

EBVpoly is an allogeneic cytotoxic T-lymphocyte (CTL) therapy developed by Atara Biotherapeutics, under an exclusive worldwide license from QIMR Berghofer Medical Research Institute. This "off-the-shelf" cell therapy is designed to target and eliminate cells infected with the Epstein-Barr virus (EBV). It is being developed for the treatment of various cancers, including gastric cancer, nasopharyngeal carcinoma, and glioblastoma multiforme, as well as autoimmune disorders such as multiple sclerosis.

Beyond the preview

Go deeper on EBVpoly.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBVpoly.

Explore the full profile